secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2023-05-19T23:59:59+00:00
Accession:  0001493152-23-018355
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa Therapeutics board members Katrin Rupalla and Daniel O'Connor resign effective May 18
--------------------------------------------------------------------------------

- Dr. Katrin Rupalla resigned to pursue opportunity that precludes board service.
- Daniel O'Connor stepped down after becoming CEO of Ambrx Biopharma; no disagreement.
- No successor directors announced; Chairman Stephen Glover thanked outgoing members.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223018355/0001493152-23-018355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223018355/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-018355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer